Merck & Co.
AWARDS
NEWS
Chinese biopharmaceutical company, Changsheng Bio-Technology, is under investigation by Chinese regulators for allegedly falsifying data for a number of products.
Merck presented results from Week 96 of its Phase III DRIVE-FORWARD clinical trial of doravirine in HIV. The data was presented in an abstract at the 22nd International AIDS Conference being held in Amsterdam.
Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year.
So far in 2018, it’s been a good year for biotech initial public offerings (IPOs). According to a Crunchbase News article, in the second quarter of this year alone, there were at least 16 U.S. venture-backed biotech and healthcare IPOs—compared to only 11 tech IPOs in the same period.
It was reported today that U.S.-based Merck & Co. will lower the price of some of its drug. It appears to be rippling through the industry, largely in an attempt to stay out of the way of Trump’s attack-tweets.
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
JOBS
IN THE PRESS